Who Paid My Doc
A Phase I/II Observer-Blind, Randomized, Multi-Center Trial to Evaluat
Research payments
$7,814,402
Through program year 2025, $7,814,402 in research payments was reported against A Phase I/II Observer-Blind, Randomized, Multi-Center Trial to Evaluat, across 478 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $780,111 | 55 |
| 2024 | Research | $1,460,921 | 347 |
| 2023 | Research | $5,573,370 | 76 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jaynier Moya Pembroke Pines, FL Named on 41 payments
- Kenneth Kim Long Beach, CA Named on 38 payments
- Scott Striplin Covington, LA Named on 32 payments
- Bonnie Colville Houston, TX Named on 31 payments
- Charles Thompson Anderson, SC Named on 26 payments
- Almena Free Anniston, AL Named on 25 payments
- Crystal Faudere El Dorado, KS Named on 20 payments
- Paul Pickrell Austin, TX Named on 19 payments
- Mary Bailey Norfolk, VA Named on 18 payments
- Harry Studdard Mobile, AL Named on 18 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.